Tissue factor: (Patho)physiology and cellular biology

Blood Coagulation and Fibrinolysis

Volumn 15, Issue 7, 2004, Pages 521-538

  Eilertsen, Karl Erik ^a   Østerud, Bjarne ^a  

^a UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Antithrombotic; Coagulation; Decryption; Hemostasis; Monocytes; Thrombosis; Tissue factor

Indexed keywords

A 183; A 183X; ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; ACTIVE SITE INACTIVATED FACTOR 7A; ANTICOAGULANT AGENT; ANTIOXIDANT; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 7A INHIBITOR; BLOOD CLOTTING FACTOR 9; CURCUMIN; DITHIOCARBAMIC ACID; E 76; FIBRIN; IXOLARIS; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY D3H44; PHA 927F; PROTEIN INHIBITOR; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; SYNTHETIC PEPTIDE; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; BIOCHEMISTRY; BLOOD CLOTTING; BLOOD VESSEL INJURY; BLOOD VESSEL WALL; CANCER; CLINICAL TRIAL; COMPLEX FORMATION; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFECT; DRUG EFFICACY; FIBRIN CLOT; FIBRIN DEPOSITION; HEMOSTASIS; HUMAN; NONHUMAN; PATHOGENICITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SEPSIS; THROMBOSIS;

ANIMALS; ARTERIOSCLEROSIS; BLOOD COAGULATION; BLOOD COAGULATION DISORDERS; BLOOD COAGULATION FACTORS; BLOOD VESSELS; DISSEMINATED INTRAVASCULAR COAGULATION; FIBRIN; GENE EXPRESSION REGULATION; HUMANS; NEOPLASMS; SEPSIS; THROMBOPLASTIN; THROMBOSIS;

EID: 5644234913     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200409000-00001     Document Type: Review

References (236)

1. Bach RR. Initiation of coagulation by tissue factor. CRC Crit Rev Biochem 1988; 23:339-368.
2. Monroe DM, Hoffman M. A cell-based model of hemostasis. Thromb Haemost 2001; 85:958-965.
3. Butenas S, Mann KG. Blood coagulation. Biochemistry (Mosc) 2002; 67:3-12.
4. Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993; 81:734-744.
5. Østerud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc Natl Acad Sci USA 1977; 74:5260-5264.
6. Butenas S, van't Veer C, Mann KG. Evaluation of the initiation phase of blood coagulation using ultrasensitive assays for serine proteases. J Biol Chem 1997; 272:21527-21533.
7. Lawson JH, Kalafatis M, Stram S, Mann KG. A model for the tissue factor pathway to thrombin. I. An empirical study. J Biol Chem 1994; 269:23357-23366.
8. Rosing J, van Rijn JL, Bevers EM, van Dieijen G, Comfurius P, Zwaal RF. The role of activated human platelets in prothrombin and factor X activation. Blood 1985; 65:319-332.
9. Tans G, Rosing J, Thomassen MC, Heeb MJ, Zwaal RF, Griffin JH. Comparison of anticoagulant and procoagulant activities of stimulated platelets and platelet-derived microparticles. Blood 1991; 77:2641-2648.
10. Nesheim ME, Taswell JB, Mann KG. The contribution of bovine Factor V and Factor Va to the activity of prothrombinase. J Biol Chem 1979; 254:10952-10962.
11. Kalafatis M, Swords NA, Rand MD, Mann KG. Membrane-dependent reactions in blood coagulation: role of the vitamin K-dependent enzyme complexes. Biochim Biophys Acta 1994; 1227:113-129.
12. Pieters J, Lindhout T, Hemker HC. In situ-generated thrombin is the only enzyme that effectively activates factor VIII and factor V in thromboplastin-activated plasma. Blood 1989; 74:1021-1024.
13. Gailani D, Braze GJ, Jr. Factor XI activation in a revised model of blood coagulation. Science 1991; 253:909-912.
14. Shen L, Lorand L. Contribution of fibrin stabilization to clot strength. Supplementation of factor XIII-deficient plasma with the purified zymogen. J Clin Invest 1983; 71:1336-1341.
15. Naski MC, Lorand L, Shafer JA. Characterization of the kinetic pathway for fibrin promotion of alpha-thrombin-catalyzed activation of plasma factor XIII. Biochemistry 1991; 30:934-941.
16. Bailey K, Bettelheim F, Lorand L, Middlebrook W. Action of thrombin in the clotting of fibrinogen. Nature 1951; 167:233-234.
17. Edgington TS, Mackman N, Brand K, Ruf W. The structural biology of expression and function of tissue factor. Thromb Haemost 1991; 66:67-79.
18. Carmeliet P, Mackman N, Moons L, Luther T, Gressens P, Van Vlaenderen I, et al. Role of tissue factor in embryonic blood vessel development. Nature 1996; 383:73-75.
19. Bugge TH, Xiao Q, Kombrinck KW, Flick MJ, Holmback K, Danton MJ, et al. Fatal embryonic bleeding events in mice lacking tissue factor, the cell-associated initiator of blood coagulation. Proc Natl Acad Sci USA 1996; 93:6258-6263.
20. Toomey JR, Kratzer KE, Lasky NM, Stanton JJ, Broze GJ, Jr. Targeted disruption of the murine tissue factor gene results in embryonic lethality. Blood 1996; 88:1583-1587.
21. Contrino J, Hair G, Kreutzer DL, Rickles FR. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med 1996; 2:209-215.
22. Nakagawa K, Zhang Y, Tsuji H, Yoshizumi M, Kasahara T, Nishimura H, et al. The angiogenic effect of tissue factor on tumors and wounds. Semin Thromb Hemost 1998; 24:207-210.
23. 2+ signals in J82 cells, transfected COS-1 cells, Madin-Darby canine kidney cells and in human endothelial cells induced to synthesize tissue factor. J Biol Chem 1995; 270:4650-4660.
24. Sørensen BB, Freskgard PO, Nielsen LS, Rao LV, Ezban M, Petersen LC. Factor VIIa-induced p44/42 mitogen-activated protein kinase activation requires the proteolytic activity of factor VIIa and is independent of the tissue factor cytoplasmic domain. J Biol Chem 1999; 274:21349-21354.
25. Mueller BM, Reisfeld RA, Edgington TS, Ruf W. Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci USA 1992; 89:11832-11836.
26. Ott I, Fischer EG, Miyagi Y, Mueller BM, Ruf W. A role for tissue factor in cell adhesion and migration mediated by interaction with actin-binding protein 280. J Cell Biol 1998; 140:1241-1253.
27. Randolph GJ, Luther T, Albrecht S, Magdolen V, Muller WA. Role of tissue factor in adhesion of mononuclear phagocytes to and trafficking through endothelium in vitro. Blood 1998; 92:4167-4177.
28. Taylor FB, Chang AC, Peer G, Li A, Ezban M, Hedner U. Active site inhibited factor VIIa (DEGR VIIa) attenuates the coagulant and interleukin-6 and -8, but not tumor necrosis factor, responses of the baboon to LD100 Escherichia coli. Blood 1998; 91:1609-1615.
29. Camerer E, Gjernes E, Wiiger M, Pringle S, Prydz H. Binding of factor VIIa to tissue factor on keratinocytes induces gene expression. J Biol Chem 2000; 275:6580-6585.
30. Morrissey JH, Fakhrai H, Edgington TS. Molecular cloning of the cDNA for tissue factor, the cellular receptor for the initiation of the coagulation protease cascade. Cell 1987; 50:129-135.
31. Spicer EK, Horton R, Bloem L, Bach R, Williams KR, Guha A, et al. Isolation of cDNA clones coding for human tissue factor: primary structure of the protein and cDNA. Proc Natl Acad Sci USA 1987; 84:5148-5152.
32. Fisher KL, Gorman CM, Vehar GA, O'Brien DP, Lawn RM. Cloning and expression of human tissue factor cDNA. Thromb Res 1987; 48:89-99.
33. Scarpati EM, Wen D, Broze GJ, Jr, Miletich JP, Flandermeyer RR, Siegel NR, et al. Human tissue factor: cDNA sequence and chromosome localization of the gene. Biochemistry 1987; 26:5234-5238.
34. Brand K, Fowler BJ, Edgington TS, Mackman N. Tissue factor mRNA in THP-1 monocytic cells is regulated at both transcriptional and posttranscriptional levels in response to lipopolysaccharide. Mol Cell Biol 1991; 11:4732-4738.
35. Mackman N, Morrissey JH, Fowler B, Edgington TS. Complete sequence of the human tissue factor gene, a highly regulated cellular receptor that initiates the coagulation protease cascade. Biochemistry 1989; 28:1755-1762.
36. Kao FT, Hartz J, Horton R, Nemerson Y, Carson SD. Regional assignment of human tissue factor gene (F3) to chromosome 1p21-p22. Somat Cell Mol Genet 1988; 14:407-410.
37. Carson SD, Henry WM, Shows TB. Tissue factor gene localized to human chromosome 1 (1pter-1p21). Science 1985; 229:991-993.
38. Mackman N. Regulation of the tissue factor gene. Thromb Haemost 1997; 78:747-754.
39. Armesilla AL, Lorenzo E, Gomez del Arco P, Martinez-Martinez S, Alfranca A, Redondo JM. Vascular endothelial growth factor activates nuclear factor of activated T cells in human endothelial cells: a role for tissue factor gene expression. Mol Cell Biol 1999; 19:2032-2043.
40. Fleck RA, Rao LV, Rapaport SI, Varki N. Localization of human tissue factor antigen by immunostaining with monospecific, polyclonal anti-human tissue factor antibody. Thromb Res 1990; 59:421-437.
41. Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol 1989; 134:1087-1097.
42. Cui MZ, Parry GC, Oeth P, Larson H, Smith M, Huang RP, et al. Transcriptional regulation of the tissue factor gene in human epithelial cells is mediated by Sp1 and EGR-1. J Biol Chem 1996; 271:2731-2739.
43. Krikun G, Schatz F, Mackman N, Guller S, Demopoulos R, Lockwood CJ. Regulation of tissue factor gene expression in human endometrium by transcription factors Sp1 and Sp3. Mol Endocrinol 2000; 14:393-400.
44. Oeth P, Parry GC, Mackman N. Regulation of the tissue factor gene in human monocytic cells. Role of AP-1, NF-kappa B/Rel, and Sp1 proteins in uninduced and lipopolysaccharide-induced expression. Arterioscler Thromb Vasc Biol 1997; 17:365-374.
45. Parry GC, Mackman N. Transcriptional regulation of tissue factor expression in human endothelial cells. Arterioscler Thromb Vasc Biol 1995; 15:612-621.
46. Mackman N, Brand K, Edgington TS. Lipopolysaccharide-mediated transcriptional activation of the human tissue factor gene in THP-1 monocytic cells requires both activator protein 1 and nuclear factor kappa B binding sites. J Exp Med 1991; 174:1517-1526.
47. Mechtcheriakova D, Wlachos A, Holzmuller H, Binder BR, Hofer E. Vascular endothelial cell growth factor-induced tissue factor expression in endothelial cells is mediated by EGR-1. Blood 1999; 93:3811-3823.
48. Cui MZ, Parry GC, Edgington TS, Mackman N. Regulation of tissue factor gene expression in epithelial cells. Induction by serum and phorbol 12-myristate 13-acetate. Arterioscler Thromb 1994; 14:807-814.
49. Guha M, O'Connell MA, Pawlinski R, Hollis A, McGovern P, Yan SF, et al. Lipopolysaccharide activation of the MEK-ERK1/2 pathway in human monocytic cells mediates tissue factor and tumor necrosis factor alpha expression by inducing Elk-1 phosphorylation and Egr-1 expression. Blood 2001; 98:1429-1439.
50. Houston P, Dickson MC, Ludbrook V, White B, Schwachtgen JL, McVey JH, et al. Fluid shear stress induction of the tissue factor promoter in vitro and in vivo is mediated by Egr-1. Arterioscler Thromb Vasc Biol 1999; 19:281-289.
51. Stenina OI, Poptic EJ, DiCorleto PE. Thrombin activates a Y box-binding protein (DNA-binding protein B) in endothelial cells. J Clin Invest 2000; 106:579-587.
52. Bizios R, Lai L, Fenton JW, 2nd, Malik AB. Thrombin-induced thromboxane generation by neutrophils and lymphocytes: dependence on enzymic site. J Cell Physiol 1987; 132:359-362.
53. Bar-Shavit R, Kahn A, Wilner GD, Fenton JW, 2nd. Monocyte chemotaxis: stimulation by specific exosite region in thrombin. Science 1983; 220:728-731.
54. Joseph S, MacDermot J. The N-terminal thrombin receptor fragment SFLLRN, but not catalytically inactive thrombin-derived agonists, activate U937 human monocytic cells: evidence for receptor hydrolysis in thrombin-dependent signalling. Biochem J 1993; 290:571-577.
55. Glusa E, Paintz M, Bretschneider E. Relaxant and contractile responses of porcine pulmonary arteries to thrombin and thrombin receptor activating peptides. Semin Thromb Hemost 1996; 22:261-265.
56. Strukova SM, Chistov IV, Umarova BA, Dugina TN, Storozhevykh TP, Pinelis VG, et al. Modulation of mast cell activity by a peptide agonist of the thrombin receptor: role of nitric oxide. Biochemistry (Mosc) 1999; 64:658-664.
57. Davey MG, Luscher EF. Actions of thrombin and other coagulant and proteolytic enzymes on blood platelets. Nature 1967; 216:857-858.
58. Ruf W, Edgington TS. Structural biology of tissue factor, the initiator of thrombogenesis in vivo. FASEB J 1994; 8:385-390.
59. Paborsky LR, Tate KM, Harris RJ, Yansura DG, Band L, McCray G, et al. Purification of recombinant human tissue factor. Biochemistry 1989; 28:8072-8077.
60. Bach R, Konigsberg WH, Nemerson Y. Human tissue factor contains thioester-linked palmitate and stearate on the cytoplasmic half-cystine. Biochemistry 1988; 27:4227-4231.
61. Harlos K, Martin DM, O'Brien DP, Jones EY, Stuart DI, Polikarpov I, et al. Crystal structure of the extracellular region of human tissue factor. Nature 1994; 370:662-666.
62. Muller YA, Ultsch MH, Kelley RF, de Vos AM. Structure of the extracellular domain of human tissue factor: location of the factor VIIa binding site. Biochemistry 1994; 33:10864-10870.
63. Muller YA, Ultsch MH, de Vos AM. The crystal structure of the extracellular domain of human tissue factor refined to 1.7 A resolution. J Mol Biol 1996; 256:144-159.
64. Ruf W, Rehemtulla A, Morrissey JH, Edgington TS. Phospholipid-independent and -dependent interactions required for tissue factor receptor and cofactor function. J Biol Chem 1991; 266:2158-2166.
65. Bach R, Gentry R, Nemerson Y. Factor VII binding to tissue factor in reconstituted phospholipid vesicles: induction of cooperativity by phosphatidylserine. Biochemistry 1986; 25:4007-4020.
66. Kunzelmann-Marche C, Satta N, Toti F, Zhang Y, Nawroth PP, Morrissey JH, et al. The influence exerted by a restricted phospholipid microenvironment on the expression of tissue factor activity at the cell plasma membrane surface. Thromb Haemost 2000; 83:282-289.
67. Morrissey JH. Tissue factor: an enzyme cofactor and a true receptor. Thromb Haemost 2001; 86:66-74.
68. Banner DW, D'Arcy A, Chene C, Winkler FK, Guha A, Konigsberg WH, et al. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature 1996; 380:41-46.
69. Zhang E, St Charles R, Tulinsky A. Structure of extracellular tissue factor complexed with factor VIIa inhibited with a BPTI mutant. J Mol Biol 1999; 285:2089-2104.
70. Ruf W, Miles DJ, Rehemtulla A, Edgington TS. Tissue factor residues 157-167 are required for efficient proteolytic activation of factor X and factor VII. J Biol Chem 1992; 267:22206-22210.
71. Ruf W, Schullek JR, Stone MJ, Edgington TS. Mutational mapping of functional residues in tissue factor: identification of factor VII recognition determinants in both structural modules of the predicted cytokine receptor homology domain. Biochemistry 1994; 33:1565-1572.
72. Schullek JR, Ruf W, Edgington TS. Key ligand interface residues in tissue factor contribute independently to factor VIIa binding. J Biol Chem 1994; 269:19399-19403.
73. Rehemtulla A, Ruf W, Edgington TS. The integrity of the cysteine 186-cysteine 209 bond of the second disulfide loop of tissue factor is required for binding of factor VII. J Biol Chem 1991; 266:10294-10299.
74. Gibbs CS, McCurdy SN, Leung LL, Paborsky LR. Identification of the factor VIIa binding site on tissue factor by homologous loop swap and alanine scanning mutagenesis. Biochemistry 1994; 33:14003-14010.
75. Kelley RF, Costas KE, O'Connell MP, Lazarus RA. Analysis of the factor VIIa binding site on human tissue factor: effects of tissue factor mutations on the kinetics and thermodynamics of binding. Biochemistry 1995; 34:10383-10392.
76. McCallum CD, Su B, Neuenschwander PF, Morrissey JH, Johnson AE. Tissue factor positions and maintains the factor VIIa active site far above the membrane surface even in the absence of the factor VIIa Gla domain. A fluorescence resonance energy transfer study. J Biol Chem 1997; 272:30160-30166.
77. McCallum CD, Hapak RC, Neuenschwander PF, Morrissey JH, Johnson AE. The location of the active site of blood coagulation factor VIIa above the membrane surface and its reorientation upon association with tissue factor. A fluorescence energy transfer study. J Biol Chem 1996; 271:28168-28175.
78. Giesen PL, Rauch U, Bohrmann B, Kling D, Roque M, Fallon JT, et al. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci USA 1999; 96:2311-2315.
79. Østerud B, Flægstad T. Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection: related to an unfavourable prognosis. Thromb Haemost 1983; 49:5-7.
80. Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989; 86:2839-2843.
81. Drake TA, Ruf W, Morrissey JH, Edgington TS. Functional tissue factor is entirely cell surface expressed on lipopolysaccharide-stimulated human blood monocytes and a constitutively tissue factor-producing neoplastic cell line. J Cell Biol 1989; 109:389-395.
82. Flossel C, Luther T, Muller M, Albrecht S, Kasper M. Immunohistochemical detection of tissue factor (TF) on paraffin sections of routinely fixed human tissue. Histochemistry 1994; 101:449-453.
83. Kato K, Elsayed YA, Namoto M, Nakagawa K, Sueishi K. Enhanced expression of tissue factor activity in the atherosclerotic aortas of cholesterol-fed rabbits. Thromb Res 1996; 82:335-347.
84. Drake TA, Cheng J, Chang A, Taylor FB, Jr. Expression of tissue factor, thrombomodulin, and E-selectin in baboons with lethal Escherichia coli sepsis. Am J Pathol 1993; 142:1458-1470.
85. Semeraro N, Triggiani R, Montemurro P, Cavallo LG, Colucci M. Enhanced endothelial tissue factor but normal thrombomodulin in endotoxin-treated rabbits. Thromb Res 1993; 71:479-486.
86. Todoroki H, Nakamura S, Higure A, Okamoto K, Takeda S, Nagata N, et al. Neutrophils express tissue factor in a monkey model of sepsis. Surgery 2000; 127:209-216.
87. Erlich J, Fearns C, Mathison J, Ulevitch RJ, Mackman N. Lipopolysaccharide induction of tissue factor expression in rabbits. Infect Immun 1999; 67:2540-2546.
88. Pawlinski R, Pedersen B, Kehrie B, Aird WC, Frank RD, Guha M, et al. Regulation of tissue factor and inflammatory mediators by Egr-1 in a mouse endotoxemia model. Blood 2003; 101:3940-3947.
89. Hara S, Asada Y, Hatakeyama K, Marutsuka K, Sato Y, Kisanuki A, et al. Expression of tissue factor and tissue factor pathway inhibitor in rats lungs with lipopolysaccharide-induced disseminated intravascular coagulation. Lab Invest 1997; 77:581-589.
90. Mackman N, Sawdey MS, Keeton MR, Loskutoff DJ. Murine tissue factor gene expression in vivo. Tissue and cell specificity and regulation by lipopolysaccharide. Am J Pathol 1993; 143:76-84.
91. Solberg S, Østerud B, Larsen T, Sørlie D. Lack of ability to synthesize tissue factor by endothelial cells in intact human saphenous veins. Blood Coagul Fibrinolysls 1990; 1:595-600.
92. Brox JH, Østerud B, Bjørklid E, Fenton JW, 2nd. Production and availability of thromboplastin in endothelial cells: the effects of thrombin, endotoxin and platelets. Br J Haematol 1984; 57:239-246.
93. Conway EM, Bach R, Rosenberg RD, Konigsberg WH. Tumor necrosis factor enhances expression of tissue factor mRNA in endothelial cells. Thromb Res 1989; 53:231-241.
94. Holzmuller H, Moll T, Hofer-Warbinek R, Mechtcheriakova D, Binder BR, Hofer E. A transcriptional represser of the tissue factor gene in endothelial cells. Arterioscler Thromb Vasc Biol 1999; 19:1804-1811.
95. Østerud B, Bjørklid E. The production and availability of tissue thromboplastin in cellular populations of whole blood exposed to various concentrations of endotoxin. An assay for detection of endotoxin. Scand J Haematol 1982; 29:175-184.
96. Lerner RG, Goldstein R, Cummings G, Lange K. Stimulation of human leukocyte thromboplastic activity by endotoxin. Proc Soc Exp Biol Med 1971; 138:145-148.
97. Rivers RP, Hathaway WE, Weston WL. The endotoxin-induced coagulant activity of human monocytes. Br J Haematol 1975; 30:311-316.
98. Morrissey JH. Tissue factor: in at the start ... and the finish? J Thromb Haemost 2003; 1:878-880.
99. Satta N, Toti F, Feugeas O, Bohbot A, Dachary-Prigent J, Eschwege V, et al. Monocyte vesiculation is a possible mechanism for dissemination of membrane-associated procoagulant activities and adhesion molecules after stimulation by lipopolysaccharide. J Immunol 1994; 153:3245-3255.
100. Nieuwland R, Berckmans RJ, Rotteveel-Eijkman RC, Maquelin KN, Roozendaal KJ, Jansen PG, et al. Cell-derived microparticles generated in patients during cardiopulmonary bypass are highly procoagulant. Circulation 1997; 96:3534-3541.
101. Mallat Z, Benamer H, Hugel B, Benessiano J, Steg PG, Freyssinet JM, et al. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation 2000; 101:841-843.
102. Misumi K, Ogawa H, Yasue H, Soejima H, Suefuji H, Nishiyama K, et al. Comparison of plasma tissue factor levels in unstable and stable angina pectoris. Am J Cardiol 1998; 81:22-26.
103. Suefuji H, Ogawa H, Yasue H, Kaikita K, Soejima H, Motoyama T, et al. Increased plasma tissue factor levels in acute myocardial infarction. Am Heart J 1997; 134:253-259.
104. Todoroki H, Higure A, Okamoto K, Okazaki K, Nagafuchi Y, Takeda S, et al. Possible role of platelet-activating factor in the in vivo expression of tissue factor in neutrophils. J Surg Res 1998; 80:149-155.
105. Zillmann A, Luther T, Muller I, Kotzsch M, Spannagl M, Kauke T, et al. Platelet-associated tissue factor contributes to the collagen-triggered activation of blood coagulation. Biochem Biophys Res Commun 2001; 281:603-609.
106. Siddiqui FA, Desai H, Amirkhosravi A, Amaya M, Francis JL. The presence and release of tissue factor from human platelets. Platelets 2002; 13:247-253.
107. Balasubramanian V, Grabowski E, Bini A, Nemerson Y. Platelets, circulating tissue factor, and fibrin colocalize in ex vivo thrombi: real-time fluorescence images of thrombus formation and propagation under defined flow conditions. Blood 2002; 100:2787-2792.
108. Amengual O, Atsumi T, Khamashta MA, Hughes GR. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost 1998; 79:276-281.
109. Asakura H, Kamikubo Y, Goto A, Shiratori Y, Yamazaki M, Jokaji H, et al. Role of tissue factor in disseminated intravascular coagulation. Thromb Res 1995; 80:217-224.
110. Key NS, Slungaard A, Dandelet L, Nelson SC, Moertel C, Styles LA, et al. Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. Blood 1998; 91:4216-4223.
111. Pernerstorfer T, Stohlawetz P, Hollenstein U, Dzirlo L, Eichler HG, Kapiotis S, et al. Endotoxin-induced activation of the coagulation cascade in humans: effect of acetylsalicylic acid and acetaminophen. Arterioscler Thromb Vasc Biol 1999; 19:2517-2523.
112. Higure A, Okamoto K, Hirata K, Todoroki H, Nagafuchi Y, Takeda S, et al. Macrophages and neutrophils infiltrating into the liver are responsible for tissue factor expression in a rabbit model of acute obstructive cholangitis. Thromb Haemost 1996; 75:791-795.
113. Østerud B, Rao LV, Olsen JO. Induction of tissue factor expression in whole blood: lack of evidence for the presence of tissue factor expression in granulocytes. Thromb Haemost 2000; 83:861-867.
114. Østerud B, Bjørklid E. The tissue factor pathway in disseminated intravascular coagulation. Semin Thromb Hemost 2001; 27:605-618.
115. Østerud B, Bjørklid E. Blood borne tissue factor (including microparticles). In: ten Cate H (editor): Molecular mechanisms of disseminated intravascular coagulation: Georgetown, TX: Landes Bioscience; 2001. Available online: http://Eurekah.com.
116. Conde I, Shrimpton CN, Thiagarajan P, Lopez JA. Tissue factor-bearing microparticles arise from monocyte lipid rafts and can fuse with activated platelets, consolidating all of the membrane-bound coagulation reactions on the platelet surface [Abstract OC146]. J Thromb Haemost 2003; 1(suppl 1).
117. Rauch U, Bonderman D, Bohrmann B, Badimon JJ, Himber J, Riederer MA, et al. Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor. Blood 2000; 96:170-175.
118. Combes V, Simon A-C, Grau G-E, Arnoux D, Camoin L, Sabatier F, et al. In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J Clin Invest 1999; 104:93-102.
119. Nieuwland R, Berckmans RJ, McGregor S, Boing AN, Romijn FP, Westendorp RG, et al. Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. Blood 2000; 95:930-935.
120. Schecter AD, Spirn B, Rossikhina M, Giesen PL, Bogdanov V, Fallon JT, et al. Release of active tissue factor by human arterial smooth muscle cells. Circ Res 2000; 87:126-132.
121. Bogdanov VY, Balasubramanian V, Hathcock J, Vele O, Lieb M, Nemerson Y. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med 2003; 9:458-462.
122. Sturk-Maquelin KN, Nieuwland R, Romijn FP, Eijsman L, Hack CE, Sturk A. Pro- and non-coagulant forms of non-cell-bound tissue factor in vivo. J Thromb Haemost 2003; 1:1920-1926.
123. Rich KC, Robins RA, Stiehm ER. Procoagulant activity of human mononuclear leukocytes: dissociation of the effect of mitogens on procoagulant activity and mitogen-stimulated lymphocyte proliferation. Pediatr Res 1981; 15:38-43.
124. Barrowcliffe TW, Fabregas P, Jardi M, Cancelas J, Rabaneda M, Feiez J. Procoagulant activity of T lymphoblastoid cells due to exposure of negatively charged phospholipid. Thromb Haemost 2002; 87:442-449.
125. Barrowcliffe TW, Marshall DE, Trickett LP, Hubbard AR, Gray E, Thorpe R. Procoagulant activity of T lymphoblastoid cells in extrinsic and intrinsic coagulation systems. Thromb Haemost 1989; 62:880-884.
126. Coeugniet E, Bendixen G. Lymphokines and thrombosis. II. Procoagulant activity produced by human lymphocytes stimulated with concanavalin A (con-A). Acta Allergol 1976; 31:107-115.
127. Gregory SA, Morrissey JH, Edgington TS. Regulation of tissue factor gene expression in the monocyte procoagulant response to endotoxin. Mol Cell Biol 1989; 9:2752-2755.
128. Ahern SM, Miyata T, Sadler JE. Regulation of human tissue factor expression by mRNA turnover. J Biol Chem 1993; 268:2154-2159.
129. Schecter AD, Giesen PL, Taby O, Rosenfield CL, Rossikhina M, Fyfe BS, et al. Tissue factor expression in human arterial smooth muscle cells. TF is present in three cellular pools after growth factor stimulation. J Clin Invest 1997; 100:2276-2285.
130. Ryan J, Brett J, Tijburg P, Bach RR, Kisiel W, Stern D. Tumor necrosis factor-induced endothelial tissue factor is associated with subendothelial matrix vesicles but is not expressed on the apical surface. Blood 1992; 80:966-974.
131. van der Logt CP, Dirven RJ, Reitsma PH, Bertina RM. Expression of tissue factor and tissue factor pathway inhibitor in monocytes in response to bacterial lipopolysaccharide and phorbolester. Blood Coagul Fibrinolysis 1994; 5:211-220.
132. Niemetz J, Herbert V. The role of protein synthesis on the generation of tissue factor activity by leukocytes. Proc Soc Exp Biol Med 1972; 139:1276-1279.
133. Lindmark E, Tenno T, Siegbahn A. Role of platelet P-selectin and CD40 ligand in the induction of monocytic tissue factor expression. Arterioscler Thromb Vasc Biol 2000; 20:2322-2328.
134. Wolberg AS, Monroe DM, Roberts HR, Hoffman MR. Tissue factor deencryption: ionophore treatment induces changes in tissue factor activity by phosphatidylserine-dependent and -independent mechanisms. Blood Coagul Fibrinolysis 1999; 10:201-210.
135. Greeno EW, Bach RR, Moldow CF. Apoptosis is associated with increased cell surface tissue factor procoagulant activity. Lab Invest 1996; 75:281-289.
136. Le DT, Rapaport SI, Rao LV. Relations between factor VIIa binding and expression of factor VIIa/tissue factor catalytic activity on cell surfaces. J Biol Chem 1992; 267:15447-15454.
137. Camerer E, Pringle S, Skartlien AH, Wiiger M, Prydz K, Kolsto AB, et al. Opposite sorting of tissue factor in human umbilical vein endothelial cells and Madin-Darby canine kidney epithelial cells. Blood 1996; 88:1339-1349.
138. Maynard JR, Heckman CA, Pitlick FA, Nemerson Y. Association of tissue factor activity with the surface of cultured cells. J Clin Invest 1975; 55:814-824.
139. Hansen CB, van Deurs B, Petersen LC, Rao LV. Discordant expression of tissue factor and its activity in polarized epithelial cells. Asymmetry in anionic phospholipid availability as a possible explanation. Blood 1999; 94:1657-1664.
140. Bjørklid E, Storm E. Purification and some properties of the protein component of tissue thromboplastin from human brain. Biochem J 1977; 165:89-96.
141. Bach R, Rifkin DB. Expression of tissue factor procoagulant activity: regulation by cytosolic calcium. Proc Natl Acad Sci USA 1990; 87:6995-6999.
142. Bach RR, Moldow CF. Mechanism of tissue factor activation on HL-60 cells. Blood 1997; 89:3270-3276.
143. Carson SD, Perry GA, Pirruccello SJ. Fibroblast tissue factor: calcium and ionophore induce shape changes, release of membrane vesicles, and redistribution of tissue factor antigen in addition to increased procoagulant activity. Blood 1994; 84:526-534.
144. Roy S, Paborsky LR, Vehar GA. Self-association of tissue factor as revealed by chemical crosslinking. J Biol Chem 1991; 266:4665-4668.
145. Donate F, Kelly CR, Ruf W, Edgington TS. Dimerization of tissue factor supports solution-phase autoactivation of factor VII without influencing proteolytic activation of factor X. Biochemistry 2000; 39:11467-11476.
146. Sevinsky JR, Rao LV, Ruf W. Ligand-induced protease receptor translocation into caveolae: a mechanism for regulating cell surface proteolysis of the tissue factor-dependent coagulation pathway. J Cell Biol 1996; 133:293-304.
147. Mulder AB, Smit JW, Bom VJ, Blom NR, Ruiters MH, Halie MR, et al. Association of smooth muscle cell tissue factor with caveolae. Blood 1996;88:1306-1313.
148. Giesen PL, Nemerson Y. Tissue factor on the loose. Semin Thromb Hemost 2000; 26:379-384.
149. Ruf W, Riewald M. Regulation of tissue factor expression. In: ten Cate H (editor): Molecular mechanisms of disseminated intravascular coagulation: Georgetown, TX: Landes Bioscience; 2001. Available online: http://Eurekah.com.
150. Iakhiaev A, Pendurthi UR, Voigt J, Ezban M, Vijaya Mohan Rao L. Catabolism of factor VIIa bound to tissue factor in fibroblasts in the presence and absence of tissue factor pathway inhibitor. J Biol Chem 1999; 274:36995-37003.
151. Hamik A, Setiadi H, Bu G, McEver RP, Morrissey JH. Down-regulation of monocyte tissue factor mediated by tissue factor pathway inhibitor and the low density lipoprotein receptor-related protein. J Biol Chem 1999; 274:4962-4969.
152. St Pierre J, Yang LY, Tamirisa K, Scherrer D, De Ciechi P, Eisenberg P, et al. Tissue factor pathway inhibitor attenuates procoagulant activity and upregulation of tissue factor at the site of balloon-induced arterial injury in pigs. Arterioscler Thromb Vasc Biol 1999; 19:2263-2268.
153. Marmur JD, Rossikhina M, Guha A, Fyfe B, Friedrich V, Mendlowitz M, et al. Tissue factor is rapidly induced in arterial smooth muscle after balloon injury. J Clin Invest 1993; 91:2253-2259.
154. Pawashe AB, Golino P, Ambrosio G, Migliaccio F, Ragni M, Pascucci I, et al. A monoclonal antibody against rabbit tissue factor inhibits thrombus formation in stenotic injured rabbit carotid arteries. Circ Res 1994; 74:56-63.
155. Thiruvikraman SV, Guha A, Roboz J, Taubman MB, Nemerson Y, Fallon JT. In situ localization of tissue factor in human atherosclerotic plaques by binding of digoxigenin-labeled factors VIIa and X. Lab Invest 1996; 75:451-461.
156. Speidel CM, Eisenberg PR, Ruf W, Edgington TS, Abendschein DR. Tissue factor mediates prolonged procoagulant activity on the luminal surface of balloon-injured aortas in rabbits. Circulation 1995; 92:3323-3330.
157. Taylor FB, Jr, Chang A, Ruf W, Morrissey JH, Hinshaw L, Catlett R, et al. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock 1991; 33:127-134.
158. Creasey AA, Chang AC, Feigen L, Wun TC, Taylor FB, Jr, Hinshaw LB. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 1993; 91:2850-2856.
159. Moons AH, Peters RJ, Cate Ht H, Bauer KA, Vlasuk GP, Buller HR, et al. Recombinant nematode anticoagulant protein c2, a novel inhibitor of tissue factor-factor VIIa activity, abrogates endotoxin-induced coagulation in chimpanzees. Thromb Haemost 2002; 88:627-631.
160. Annex BH, Denning SM, Channon KM, Sketch MH, Jr, Stack RS, Morrissey JH, et al. Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes. Circulation 1995; 91:619-622.
161. Moreno PR, Bernardi VH, Lopez-Cuellar J, Murcia AM, Palacios IF, Gold HK, et al. Macrophages, smooth muscle cells, and tissue factor in unstable angina. Implications for cell-mediated thrombogenicity in acute coronary syndromes. Circulation 1996; 94:3090-3097.
162. Toschi V, Gallo R, Lettino M, Fallon JT, Gertz SD, Fernandez-Ortiz A, et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 1997; 95:594-599.
163. Taubman MB, Fallon JT, Scheeler AD, Giesen P, Mendlowitz M, Fyfe BS, et al. Tissue factor in the pathogenesis of atherosclerosis. Thromb Haemost 1997; 78:200-204.
164. Marmur JD, Thiruvikraman SV, Fyfe BS, Guha A, Sharma SK, Ambrose JA, et al. Identification of active tissue factor in human coronary atheroma. Circulation 1996; 94:1226-1232.
165. Bonderman D, Teml A, Jakowitsch J, Adlbrecht C, Gyongyosi M, Sperker W, et al. Coronary no-reflow is caused by shedding of active tissue factor from dissected atherosclerotic plaque. Blood 2002; 99:2794-2800.
166. Hamada K, Kuratsu J, Saitoh Y, Takeshima H, Nishi T, Ushio Y. Expression of tissue factor in glioma. Noshuyo Byori 1996; 13:115-118.
167. Vrana JA, Stang MT, Grande JP, Getz MJ. Expression of tissue factor in tumor stroma correlates with progression to invasive human breast cancer: paracrine regulation by carcinoma cell-derived members of the transforming growth factor beta family. Cancer Res 1996; 56:5063-5070.
168. Koomagi R, Volm M. Tissue-factor expression in human non-small-cell lung carcinoma measured by immunohistochemistry: correlation between tissue factor and angiogenesis. Int J Cancer 1998; 79:19-22.
169. Abdulkadir SA, Carvalhal GF, Kaleem Z, Kisiel W, Humphrey PA, Catalona WJ, et al. Tissue factor expression and angiogenesis in human prostate carcinoma. Hum Pathol 2000; 31:443-447.
170. Lykke J, Nielsen HJ. The role of tissue factor in colorectal cancer. Eur J Surg Oncol 2003; 29:417-422.
171. Hembrough TA, Swartz GM, Papathanassiu A, Vlasuk GP, Rote WE, Green SJ, et al. Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism. Cancer Res 2003; 63:2997-3000.
172. Huang X, Molema G, King S, Watkins L, Edgington TS, Thorpe PE. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 1997; 275:547-550.
173. Hu P, Yan J, Sharifi J, Bai T, Khawli LA, Epstein AL. Comparison of three different targeted tissue factor fusion proteins for inducing tumor vessel thrombosis. Cancer Res 2003; 63:5046-5053.
174. Badimon L. Atherosclerosis and thrombosis: lessons from animal models. Thromb Haemost 2001; 86:356-365.
175. Badimon JJ, Lettino M, Toschi V, Fuster V, Berrozpe M, Chesebro JH, et al. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. Circulation 1999; 99:1780-1787.
176. Jang IK, Gold HK, Leinbach RC, Fallon JT, Collen D, Wilcox JN. Antithrombotic effect of a monoclonal antibody against tissue factor in a rabbit model of platelet-mediated arterial thrombosis. Arterioscler Thromb 1992; 12:948-954.
177. Ragni M, Cirillo P, Pascucci I, Scognamiglio A, D'Andrea D, Eramo N, et al. Monoclonal antibody against tissue factor shortens tissue plasminogen activator lysis time and prevents reocclusion in a rabbit model of carotid artery thrombosis. Circulation 1996; 93:1913-1918.
178. Presta L, Sims P, Meng YG, Moran P, Bullens S, Bunting S, et al. Generation of a humanized, high affinity anti-tissue factor antibody for use as a novel antithrombotic therapeutic. Thromb Haemost 2001; 85:379-389.
179. Lev EI, Marmur JD, Zdravkovic M, Osende JI, Robbins J, Delfin JA, et al. Antithrombotic effect of tissue factor inhibition by inactivated factor VIIa: an ex vivo human study. Arterioscler Thromb Vasc Biol 2002; 22:1036-1041.
180. Kirchhofer D, Tschopp TB, Baumgartner HR. Active site-blocked factors VIIa and IXa differentially inhibit fibrin formation in a human ex vivo thrombosis model. Arterioscler Thromb Vasc Biol 1995; 15:1098-1106.
181. Falati S, Gross P, Merrill-Skoloff G, Furie BC, Furie B. Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse. Nat Med 2002; 8:1175-1181.
182. Mackman N. Tissue factor: lessons from knock-outs, knock-ins and transgenic mouse models [Abstract SY22]. J Thromb Haemost 2003; 1(suppl 1).
183. Parry GC, Erlich JH, Carmeliet P, Luther T, Mackman N. Low levels of tissue factor are compatible with development and hemostasis in mice. J Clin Invest 1998; 101:560-569.
184. Himber J, Wohlgensinger C, Roux S, Damico LA, Fallon JT, Kirchhofer D, et al. Inhibition of tissue factor limits the growth of venous thrombus in the rabbit. J Thromb Haemost 2003; 1:889-895.
185. Falati S, Liu Q, Gross P, Merrill-Skoloff G, Chou J, Vandendries E, et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med 2003; 197:1585-1598.
186. Takahashi H, Sato N, Shibata A. Plasma tissue factor pathway inhibitor in disseminated intravascular coagulation: comparison of its behavior with plasma tissue factor. Thromb Res 1995; 80:339-348.
187. Rauch U, Osende JI, Fuster V, Badimon JJ, Fayad Z, Chesebro JH. Thrombus formation on atherosclerotic plaques: pathogenesis and clinical consequences. Ann Intern Med 2001; 134:224-238.
188. Ruf W, Mueller BM. Tissue factor in cancer angiogenesis and metastasis. Curr Opin Hematol 1996; 3:379-384.
189. Kelley RF, Refino CJ, O'Connell MP, Modi N, Sehl P, Lowe D, et al. A soluble tissue factor mutant is a selective anticoagulant and antithrombotic agent. Blood 1997; 89:3219-3227.
190. Himber J, Refino CJ, Burcklen L, Roux S, Kirchhofer D. Inhibition of arterial thrombosis by a soluble tissue factor mutant and active site-blocked factors IXa and Xa in the guinea pig. Thromb Haemost 2001; 85:475-481.
191. Cirillo P, Golino P, Ragni M, D'Andrea D, Calabro P, Corcione N, et al. Long-lasting antithrombotic effects of a single dose of human recombinant, active site-blocked factor VII: insights into possible mechanism(s) of action. J Thromb Haemost 2003; 1:992-998.
192. Corseaux D, Le Tourneau T, Six I, Ezekowitz MD, McFadden EP, Meurice T, et al. Enhanced monocyte tissue factor response after experimental balloon angioplasty in hypercholesterolemic rabbit: inhibition with dietary L-arginine. Circulation 1998; 98:1776-1782.
193. Shultz PJ, Raij L. Endogenously synthesized nitric oxide prevents endotoxin-induced glomerular thrombosis. J Clin Invest 1992; 90:1718-1725.
194. Fiorucci S, Mencarelii A, Meneguzzi A, Lechi A, Morelli A, del Soldato P, et al. NCX-4016 (NO-aspirin) inhibits lipopolysaccharide-induced tissue factor expression in vivo: role of nitric oxide. Circulation 2002; 106:3120-3125.
195. Bierhaus A, Zhang Y, Quehenberger P, Luther T, Haase M, Muller M, et al. The dietary pigment curcumin reduces endothelial tissue factor gene expression by inhibiting binding of AP-1 to the DNA and activation of NF-kappa B. Thromb Haemost 1997; 77:772-782.
196. Pendurthi UR, Williams JT, Rao LV. Inhibition of tissue factor gene activation in cultured endothelial cells by curcumin. Suppression of activation of transcription factors Egr-1, AP-1, and NF-kappa B. Arterioscler Thromb Vasc Biol 1997; 17:3406-3413.
197. Bohrer H, Qiu F, Zimmermann T, Zhang Y, Jllmer T, Mannel D, et al. Role of NFkappaB in the mortality of sepsis. J Clin Invest 1997; 100:972-985.
198. Drollinger AG, Netser JC, Rodgers GM. Dithiocarbamates ameliorate the effects of endotoxin in a rabbit model of disseminated intravascular coagulation. Semin Thromb Hemost 1999; 25:429-433.
199. Zhang Y, Deng Y, Wendt T, Liliensiek B, Bierhaus A, Greten J, et al. Intravenous somatic gene transfer with antisense tissue factor restores blood flow by reducing tumor necrosis factor-induced tissue factor expression and fibrin deposition in mouse meth-A sarcoma. J Clin Invest 1996; 97:2213-2224.
200. Stephens AC, Rivers RP. Suppression of human monocyte tissue factor synthesis by antisense oligodeoxynucleotide. Thromb Res 1997; 85:387-398.
201. Nakamura K, Kadotani Y, Ushigome H, Akioka K, Okamoto M, Ohmori Y, et al. Antisense oligonucleotide for tissue factor inhibits hepatic ischemic reperfusion injury. Biochem Biophys Res Commun 2002; 297:433-441.
202. Cavusoglu E, Chen I, Rappaport J, Marmur JD. Inhibition of tissue factor gene induction and activity using a hairpin ribozyme. Circulation 2002; 105:2282-2287.
203. Jankowsky E, Schwenzer B. Oligonucleotide facilitators enable a hammerhead ribozyme to cleave long RNA substrates with multiple-turnover activity. Eur J Biochem 1998; 254:129-134.
204. Holen T, Amarzguioui M, Wiiger MT, Babaie E, Prydz H. Positional effects of short interfering RNAs targeting the human coagulation trigger Tissue Factor. Nucl Acids Res 2002; 30:1757-1766.
205. Yang J, Lee GF, Riederer MA, Kelley RF. Enhancing the anticoagulant potency of soluble tissue factor mutants by increasing their affinity to factor VIIa. Thromb Haemost 2002; 87:450-458.
206. Suleymanov OD, Szalony JA, Salyers AK, LaChance RM, Parlow JJ, South MS, et al. Pharmacological interruption of acute thrombus formation with minimal hemorrhagic complications by a small molecule tissue factor/factor VIIa inhibitor: comparison to factor Xa and thrombin inhibition in a nonhuman primate thrombosis model. J Pharmacol Exp Ther 2003; 306:1115-1121.
207. Huang H, Norledge BV, Liu C, Olson AJ, Edgington TS. Selective attenuation of the extrinsic limb of the tissue factor-driven coagulation protease cascade by occupancy of a novel peptidyl docking site on tissue factor. Biochemistry 2003; 42:10619-10626.
208. Wildgoose P, Berkner KL, Kisiel W. Synthesis, purification, and characterization of an Arg152-Glu site-directed mutant of recombinant human blood clotting factor VII. Biochemistry 1990; 29:3413-3420.
209. Valentin S, Reutlingsperger CP, Nordfang O, Lindhout T. Inhibition of factor X activation at extracellular matrix of fibroblasts during flow conditions: a comparison between tissue factor pathway inhibitor and inactive factor VIIa. Thromb Haemost 1995; 74:1478-1485.
210. Harker LA, Hanson SR, Wilcox JN, Kelly AB. Antithrombotic and antilesion benefits without hemorrhagic risks by inhibiting tissue factor pathway. Haemostasis 1996; 26(suppl 1):76-82.
211. Golino P, Ragni M, Cirillo P, D'Andrea D, Scognamiglio A, Ravera A, et al. Antithrombotic effects of recombinant human, active site-blocked factor VIIa in a rabbit model of recurrent arterial thrombosis. Circ Res 1998; 82:39-46.
212. Golino P, Ragni M, Cirillo P, Scognamiglio A, Ravera A, Buono C, et al. Recombinant human, active site-blocked factor VIIa reduces infarct size and no-reflow phenomenon in rabbits. Am J Physiol Heart Circ Physiol 2000; 278:H1507-H1516.
213. Arnljots B, Soderstrom T, Ezban M, Hedner U. Effect of locally-applied active site-blocked activated factor VII (ASIS) on experimental arterial thrombosis. Blood Coagul Fibrinolysis 2000; 11(suppl 1):S145-S148.
214. Golino P, Ragni M, Cirillo P, D'Andrea D, Ravera M, Calabro P, et al. Effects of recombinant active site-blocked activated factor VII in rabbit models of carotid stenosis and myocardial infarction. Blood Coagul Fibrinolysis 2000; 11 (suppl 1):S149-S158.
215. Welty-Wolf K, Carraway M, Miller D, Ortel T, Ezban M, Ghio A, et al. Coagulation blockade prevents sepsis-induced respiratory and renal failure in baboons. Am J Respir Crit Care Med 2001; 164:1988-1996.
216. Roberge M, Santell L, Dennis MS, Eigenbrot C, Dwyer MA, Lazarus RA. A novel exosite on coagulation factor VIIa and its molecular interactions with a new class of peptide inhibitors. Biochemistry 2001; 40:9522-9531.
217. Roberge M, Peek M, Kirchhofer D, Dennis MS, Lazarus RA. Fusion of two distinct peptide exosite inhibitors of Factor VIIa. Biochem J 2002; 363:387-393.
218. Maun HR, Eigenbrot C, Lazarus RA. Engineering exosite peptides for complete inhibition of factor VIIa using a protease switch with substrate phage. J Biol Chem 2003; 278:21823-21830.
219. Szalony JA, Taite BB, Girard TJ, Nicholson NS, LaChance RM. Pharmacological intervention at disparate sites in the coagulation cascade: comparison of anti-thrombotic efficacy vs. bleeding propensity in a rat model of acute arterial thrombosis. J Thromb Thrombolysis 2002; 14:113-121.
220. Geisbert TW, Hensley LE, Jahrling PB, Larsen T, Geisbert JB, Paragas J, et al. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet 2003; 362:1953-1958.
221. Lee A, Agnelli G, Buller H, Ginsberg J, Heit J, Rote W, et al. Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation 2001; 104:74-78.
222. De Pont AC, Moons AH, De Jonge E, Meijers JC, Vlasuk GP, Rote WE, et al. Recombinant nematode anticoagulant protein c2, an inhibitor of tissue factor/factor VIIa, attenuates coagulation and the interleukin-10 response in human endotoxemia. J Thromb Haemost 2004; 2:65-70.
223. Asada Y, Hara S, Tsuneyoshi A, Hatakeyama K, Kisanuki A, Marutsuka K, et al. Fibrin-rich and platelet-rich thrombus formation on neointima: recombinant tissue factor pathway inhibitor prevents fibrin formation and neointimal development following repeated balloon injury of rabbit aorta. Thromb Haemost 1998; 80:506-511.
224. Roque M, Reis ED, Fuster V, Padurean A, Fallon JT, Taubman MB, et al. Inhibition of tissue factor reduces thrombus formation and intimal hyperplasia after porcine coronary angioplasty. J Am Coll Cardiol 2000; 36:2303-2310.
225. Abraham E, Reinhart K, Svoboda P, Seibert A, Olthoff D, Dal Nogare A, et al. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med 2001; 29:2081-2089.
226. Nakamura Y, Nakamura K, Ohta K, Matsubara H, Yutani C, Hamuro T, et al. Anti-inflammatory effects of long-lasting locally-delivered human recombinant tissue factor pathway inhibitor after balloon angioplasty. Basic Res Cardiol 2002; 97:198-205.
227. de Jonge E, Dekkers PE, Creasey AA, Hack CE, Paulson SK, Karim A, et al. Tissue factor pathway inhibitor does not influence inflammatory pathways during human endotoxemia. J Infect Dis 2001; 183:1815-1818.
228. Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003; 290:238-247.
229. Huynh TT, Davies MG, Thompson MA, Ezekowitz MD, Hagen P, Annex BH. Local treatment with recombinant tissue factor pathway inhibitor reduces the development of intimai hyperplasia in experimental vein grafts. J Vasc Surg 2001; 33:400-407.
230. Atsuchi N, Nishida T, Marutsuka K, Asada Y, Kamikubo Y, Takeshita A, et al. Combination of a brief irrigation with tissue factor pathway inhibitor (TFPI) and adenovirus-mediated local TFPI gene transfer additively reduces neointima formation in balloon-injured rabbit carotid arteries. Circulation 2001; 103:570-575.
231. Zoldhelyi P, McNatt J, Shelat HS, Yamamoto Y, Chen ZQ, Willerson JT. Thromboresistance of balloon-injured porcine carotid arteries after local gene transfer of human tissue factor pathway inhibitor. Circulation 2000; 101:289-295.
232. Zoldhelyi P, Chen ZQ, Shelat HS, McNatt JM, Willerson JT. Local gene transfer of tissue factor pathway inhibitor regulates intimal hyperplasia in atherosclerotic arteries. Proc Natl Acad Sci USA 2001; 98:4078-4083.
233. Golino P, Cirillo P, Calabro P, Ragni M, D'Andrea D, Avvedimento EV, et al. Expression of exogenous tissue factor pathway inhibitor in vivo suppresses thrombus formation in injured rabbit carotid arteries. J Am Coll Cardiol 2001; 38:569-576.
234. Yin X, Yutani C, Ikeda Y, Enjyoji K, Ishibashi-Ueda H, Yasuda S, et al. Tissue factor pathway inhibitor gene delivery using HVJ-AVE liposomes markedly reduces restenosis in atherosclerotic arteries. Cardiovasc Res 2002; 56:454-463.
235. Khouri RK, Sherman R, Buncke HJ, Jr, Feller AM, Hovius S, Benes CO, et al. A phase II trial of intraluminal irrigation with recombinant human tissue factor pathway inhibitor to prevent thrombosis in free flap surgery. Plast Reconstr Surg 2001; 107:408-415 [discussion, Plast Reconstr Surg 2001; 107:416-408].
236. Khouri RK, Sherman R, Buncke HJ, Jr, Feller AM, Hovius S, Benes CO, et al. A phase II trial of intraluminal irrigation with recombinant human tissue factor pathway inhibitor to prevent thrombosis in free flap surgery. Plast Reconstr Surg 2001; 107:408-415 [discussion, Plast Reconstr Surg 2001; 107:416-408].